Why the study?
Does Gd-DTPA-enhanced MRI detect myocardial damage in patients with secondary cardiomyopathies?
Does Gd-DTPA-enhanced MRI detect myocardial damage in patients with secondary cardiomyopathies?
Gated cardiac MRI with Gd-DTPA enhancement is a useful imaging modality for detecting and localizing myocardial damage in secondary cardiomyopathies.
Answers are grounded in this paper and cite their sources.
May support Gd-DTPA MRI for detecting myocardial damage in secondary cardiomyopathies; leaves open validation before clinical adoption.
To evaluate the myocardial damage in patients with secondary cardiomyopathies, the authors examined gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA)-enhanced magnetic resonance imaging (MRI) in 5 patients (2 with cardiac amyloidosis, 2 with acute myocarditis, 1 with cardiac thyrotoxicosis). MR images were performed at 1.5-T by using a spin echo pulse sequence before and after intravenous administration of Gd-DTPA (0.2 mmol/kg). All patients revealed distinct high-intensity areas on postcontrast images. Moreover, MRI with Gd-DTPA could determine the severity and precise regions of myocardial damage associated with secondary cardiomyopathies. It is suggested that gated cardiac MRI with Gd-DTPA enhancement is useful for detecting the myocardial damage in secondary cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Matsuoka et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: